Cardiac biomarkers are any substances, primarily proteins or enzymes, that appear in theblood because of myocardial stress or injury. Among them are the use of biomarkers in diagnosing, risk assessment and treatment of Acute Coronary Syndrome (ACS) & Heart failure.A lot of attention has been placed on the markets of the cardiac biomarkers over the recent past, especially in developed countries due to rising incidences of CVDs.. All these biomarkers are valuable in determining ailment such as MI, heart failure and other cardiovascular diseases. Rising demand for POC testing tools due to technological enhancements simultaneously coupled with a rise in the use of diagnostics also contributes significantly to the market growth. These are due to demographic changes, life style factors including smoking, hypertension, and diabetes which have led to increased occurrence of heart diseases and thereby propelling the demand for cardiac biomarker testing. Today’s healthcare systems worldwide are striving to reach a kernel diagnosis and the timely prevention of heart diseases due to the high costs and the severe impact on the organism. For these reasons, caregivers are turning to cardiac biomarkers to reduce the time it takes and the error margin in differentiation.Further, there is a growing research done to discovery new biomarkers that would offer more specific information regarding diseased heart. Moreover, constant approval of new products and their launches by market players are forming the competitive environment and driving the innovations in the market. As an example, high sensitivity troponin is one of the rather recently applied high-sensitivity assays, which is increasingly used in practice. These assays give better results to even small of myocardial damage and thus enable early treatment that improves patient’s welfare. This has greatly impacted the market growth path, as healthcare organizations, and hospitals seek better and accurate diagnostic solutions for cardiac treatment.